Million A. Tegenge
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Million A. Tegenge has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
Iftekhar Mahmood
Mahmood Clinical Pharmacology Consultancy LLC, Rockville, MD, USA
6 shared publicationsRichard Forshee
Office of Biostatistics & Epidemiology Center for Biologics Evaluation and Research US Food and Drug Administration (FDA) Silver Spring Maryland USA
4 shared publicationsRobert J. Mitkus
Office of Biostatistics & Epidemiology, Center for Biologics Evaluation and Research, FDA, Silver Spring, MD, 20993, USA; Current Address: BASF Corporation, 26 Davis Drive, Durham, NC, 27709, USA
4 shared publications- Iftekhar Mahmood
Mahmood Clinical Pharmacology Consultancy, LLC, Rockville, MD 20850, USA
3 shared publications - Marc R. Theoret
Oncology Center of Excellence, US Food and Drug Administration, Silver Spring, MD
3 shared publications - Basil Golding
Division of Plasma Derivatives, Office of Plasma Protein Therapeutics, Office of Therapeutic Products, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, USA
2 shared publications
Latest Publications
- 3 December 2025
- Published by Springer Nature in The AAPS Journal
- Vol. 28 (1) , 24
The Impact of Cognate Antigen Binding on the FcRn-mediated Transcytosis and Recycling of Monoclonal Antibodies
Immunoglobulin G (IgG) antibodies rely on neonatal Fc receptor (FcRn)-mediated recycling and transcytosis for prolonged serum half-life and tissue distribu
- 3 December 2025
- Published by Springer Nature in The AAPS Journal
- Vol. 28 (1) , 24
The Impact of Cognate Antigen Binding on the FcRn-mediated Transcytosis and Recycling of Monoclonal Antibodies
Immunoglobulin G (IgG) antibodies rely on neonatal Fc receptor (FcRn)-mediated recycling and transcytosis for prolonged serum half-life and tissue distribu
- Open Access
- 19 November 2025
- Published by MDPI AG in Antibodies
- Vol. 14 (4) , 99
Physiologically Based Pharmacokinetic Model for Prediction of Immunoglobulins Exposure in Pregnant Women
Background: Physiologically based pharmacokinetic (PBPK) modeling is applied to address clinical pharmacology issues including dose selection and exposure assessments for special populations (e.g., pediatrics, and renally or hepatically impaired patients). The objective of this study was to evaluate the predictive performance of a PBPK model for dosing assessment of intravenous immunoglobulin (IVIG) and anti-D immunoglobulin (anti-D Ig) products in pregnant women. Methods: A minimal PBPK (mPBPK) model that incorporates pregnancy-specific physiological parameters and allometric scaling approaches was developed and evaluated for predicting the exposure of IVIG and anti-D Ig in pregnant women. The concentration versus time data were obtained from the published literature. Results: The IVIG (n = 22) and anti-D Ig (n = 29) concentrations were predicted using the mPBPK model with an average fold error of 1.17 and 1.22, respectively. A total of 100% and 95% of IVIG concentrations were predicted within the 0.5–2-fold and 0.5–1.5-fold prediction error ranges, respectively. For anti-D Ig, predictions fell within the 0.5–2-fold and 0.5–1.5-fold ranges for 93% and 76% concentrations, respectively. A mPBPK model-based simulation following administration of 0.5 g/kg IVIG in 100 virtual nonpregnant and pregnant subjects revealed that the maximum plasma concentration (Cmax) was 15% lower and trough concentration (Ctrough) was 8% lower during the third trimester of pregnancy compared to nonpregnant subjects. In contrast, with flat dosing, Cmax and Ctrough were 32% and 26% lower in pregnant subjects, respectively. Overall, the model demonstrated reasonable predictive performance, and bodyweight-based dosing regimen is an acceptable approach that results in minimal change in exposure of IVIG in pregnant women.
- 19 November 2025
- Published by MDPI AG in Antibodies
- Vol. 14 (4) , 99
Open AccessPhysiologically Based Pharmacokinetic Model for Prediction of Immunoglobulins Exposure in Pregnant Women
Background: Physiologically based pharmacokinetic (PBPK) modeling is applied to address clinical pharmacology issues including dose selection and exposure assessments for special populations (e.g., pediatrics, and renally or hepatically impaired patients). The objective of this study was to evaluate the predictive performance of a PBPK model for dosing assessment of intravenous immunoglobulin (IVIG) and anti-D immunoglobulin (anti-D Ig) products in pregnant women. Methods: A minimal PBPK (mPBPK) model that incorporates pregnancy-specific physiological parameters and allometric scaling approaches was developed and evaluated for predicting the exposure of IVIG and anti-D Ig in pregnant women. The concentration versus time data were obtained from the published literature. Results: The IVIG (n = 22) and anti-D Ig (n = 29) concentrations were predicted using the mPBPK model with an average fold error of 1.17 and 1.22, respectively. A total of 100% and 95% of IVIG concentrations were predicted within the 0.5–2-fold and 0.5–1.5-fold prediction error ranges, respectively. For anti-D Ig, predictions fell within the 0.5–2-fold and 0.5–1.5-fold ranges for 93% and 76% concentrations, respectively. A mPBPK model-based simulation following administration of 0.5 g/kg IVIG in 100 virtual nonpregnant and pregnant subjects revealed that the maximum plasma concentration (Cmax) was 15% lower and trough concentration (Ctrough) was 8% lower during the third trimester of pregnancy compared to nonpregnant subjects. In contrast, with flat dosing, Cmax and Ctrough were 32% and 26% lower in pregnant subjects, respectively. Overall, the model demonstrated reasonable predictive performance, and bodyweight-based dosing regimen is an acceptable approach that results in minimal change in exposure of IVIG in pregnant women.
- 9 October 2025
- Published by Springer Nature in The AAPS Journal
- Vol. 27 (6) , 1-10
Physiologically Based Pharmacokinetic Modeling and Simulation in Regulatory Review: US FDA CBER Experience and Perspectives
Physiologically based pharmacokinetic (PBPK) modeling has emerged as a valuable tool in model-informed drug development (MIDD). This approach enables the i
- 9 October 2025
- Published by Springer Nature in The AAPS Journal
- Vol. 27 (6) , 1-10
Physiologically Based Pharmacokinetic Modeling and Simulation in Regulatory Review: US FDA CBER Experience and Perspectives
Physiologically based pharmacokinetic (PBPK) modeling has emerged as a valuable tool in model-informed drug development (MIDD). This approach enables the i
- Open Access
- 18 September 2025
- Published by Wiley in Clinical and Translational Science
- Vol. 18 (9) , e70359
Utilization of Machine Learning Approaches for Drug Clearance Prediction and Population Pharmacokinetic Covariate Analysis
Population pharmacokinetic (popPK) analysis is routinely used to evaluate drug clearance and covariate effects on pharmacokinetic parameters to support dosing recommendations. While stepwise methods are traditionally employed for covariate identification, artificial intelligence (AI) and machine learning (ML) approaches offer promising alternatives for enhancing these analyses. This proof‐of‐concept study illustrates the application of AI/ML and explainable artificial intelligence (XAI) techniques for drug clearance prediction and covariate analysis using two distinct datasets for the drugs methotrexate and remifentanil. For the larger methotrexate dataset, we utilized multiple ML models including convolutional neural networks, logistic regression, and gradient boosting and highlighted exceptional performance ( R 2 for accuracy > 0.96) in clearance prediction. XAI via SHapley Additive exPlanations (SHAP) analysis is utilized to identify vital covariates impacting clearance. Here, XAI techniques are utilized to explore how different AI/ML approaches might impact the interpretation of relationships among covariates. By examining these methods, we seek to better understand their respective strengths, limitations, and potential to provide insights for popPK analysis. The second example used a smaller dataset for the drug remifentanil and included pediatric to adult populations. Here, the performance of the ML models was more modest (maximum R 2 of 0.75), highlighting the dependence of ML techniques on adequate sample sizes. SHAP analysis confirmed age and weight as critical covariates for the clearance of remifentanil. Our findings demonstrate that AI/ML approaches can provide accurate clearance predictions and identify potentially overlooked covariates in an unbiased, hypothesis‐free manner. However, this study also emphasizes important limitations, including the requirement for sufficiently large datasets and the drug‐specific nature of trained models. These proof‐of‐concept examples illustrate how AI/ML methods can complement traditional pharmacokinetic analyses, offering additional insights while maintaining scientific rigor.
- 18 September 2025
- Published by Wiley in Clinical and Translational Science
- Vol. 18 (9) , e70359
Open AccessUtilization of Machine Learning Approaches for Drug Clearance Prediction and Population Pharmacokinetic Covariate Analysis
Population pharmacokinetic (popPK) analysis is routinely used to evaluate drug clearance and covariate effects on pharmacokinetic parameters to support dosing recommendations. While stepwise methods are traditionally employed for covariate identification, artificial intelligence (AI) and machine learning (ML) approaches offer promising alternatives for enhancing these analyses. This proof‐of‐concept study illustrates the application of AI/ML and explainable artificial intelligence (XAI) techniques for drug clearance prediction and covariate analysis using two distinct datasets for the drugs methotrexate and remifentanil. For the larger methotrexate dataset, we utilized multiple ML models including convolutional neural networks, logistic regression, and gradient boosting and highlighted exceptional performance ( R 2 for accuracy > 0.96) in clearance prediction. XAI via SHapley Additive exPlanations (SHAP) analysis is utilized to identify vital covariates impacting clearance. Here, XAI techniques are utilized to explore how different AI/ML approaches might impact the interpretation of relationships among covariates. By examining these methods, we seek to better understand their respective strengths, limitations, and potential to provide insights for popPK analysis. The second example used a smaller dataset for the drug remifentanil and included pediatric to adult populations. Here, the performance of the ML models was more modest (maximum R 2 of 0.75), highlighting the dependence of ML techniques on adequate sample sizes. SHAP analysis confirmed age and weight as critical covariates for the clearance of remifentanil. Our findings demonstrate that AI/ML approaches can provide accurate clearance predictions and identify potentially overlooked covariates in an unbiased, hypothesis‐free manner. However, this study also emphasizes important limitations, including the requirement for sufficiently large datasets and the drug‐specific nature of trained models. These proof‐of‐concept examples illustrate how AI/ML methods can complement traditional pharmacokinetic analyses, offering additional insights while maintaining scientific rigor.
- 23 July 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (19) , 4004-4009
FDA Approval Summary: Lifileucel for Unresectable or Metastatic Melanoma Previously Treated with an Anti–PD-1–Based Immunotherapy
On February 16, 2024, the FDA granted accelerated approval to lifileucel (Amtagvi, Iovance Biotherapeutics, Inc.) indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1–blocking antibody and, if BRAF V600 mutation positive, a BRAF inhibitor with or without an MEK inhibitor. Lifileucel is the first tumor-derived T-cell therapy approved by the FDA. In the phase II single-arm trial, Study C-144-01, that served as the basis for approval, the objective response rate among patients treated with lifileucel within FDA-approved dose range (7.5 × 109 to 72 × 109 viable cells, n = 73) in the primary efficacy cohort was 31.5% (95% confidence interval, 21.1%–43.4%), including three (4.1%) complete responses and 20 (27.4%) partial responses. The median duration of response was not reached (95% confidence interval, 4.1 months–not reached). Among the responders (n = 23), 56.5%, 47.8%, and 43.5% maintained durable responses at 6, 9, and 12 months, respectively. Among all patients who received lifileucel (n = 156) in the primary and supportive cohorts of Study C-144-01, 95.5% of patients experienced at least one Grade 3 treatment-emergent adverse event and 87.8% experienced at least one Grade 4 treatment-emergent adverse event. Lifileucel labeling includes a Boxed Warning for treatment-related mortality, prolonged severe cytopenia, severe infection, cardiopulmonary impairment, and renal impairment.
- 23 July 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (19) , 4004-4009
FDA Approval Summary: Lifileucel for Unresectable or Metastatic Melanoma Previously Treated with an Anti–PD-1–Based Immunotherapy
On February 16, 2024, the FDA granted accelerated approval to lifileucel (Amtagvi, Iovance Biotherapeutics, Inc.) indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1–blocking antibody and, if BRAF V600 mutation positive, a BRAF inhibitor with or without an MEK inhibitor. Lifileucel is the first tumor-derived T-cell therapy approved by the FDA. In the phase II single-arm trial, Study C-144-01, that served as the basis for approval, the objective response rate among patients treated with lifileucel within FDA-approved dose range (7.5 × 109 to 72 × 109 viable cells, n = 73) in the primary efficacy cohort was 31.5% (95% confidence interval, 21.1%–43.4%), including three (4.1%) complete responses and 20 (27.4%) partial responses. The median duration of response was not reached (95% confidence interval, 4.1 months–not reached). Among the responders (n = 23), 56.5%, 47.8%, and 43.5% maintained durable responses at 6, 9, and 12 months, respectively. Among all patients who received lifileucel (n = 156) in the primary and supportive cohorts of Study C-144-01, 95.5% of patients experienced at least one Grade 3 treatment-emergent adverse event and 87.8% experienced at least one Grade 4 treatment-emergent adverse event. Lifileucel labeling includes a Boxed Warning for treatment-related mortality, prolonged severe cytopenia, severe infection, cardiopulmonary impairment, and renal impairment.
- 15 July 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
FDA Approval Summary: Lisocabtagene Maraleucel for Relapsed or Refractory Follicular Lymphoma
In May 2024, the FDA granted accelerated approval to lisocabtagene maraleucel for the treatment of adults with relapsed or refractory (R/R) follicular lymphoma (FL) who have received two or more prior lines of systemic therapy. The single-arm, open-label, multicenter, phase 2 TRANSCEND-FL trial evaluating a single dose of lisocabtagene maraleucel in adults with R/R indolent non-Hodgkin lymphoma supported the FL indication. The trial enrolled 139 patients with R/R FL, including 107 with two or more prior lines of therapy. Of the 107 patients, 94 patients comprised the primary efficacy population and the independent review committee-assessed overall response rate was 95.7% (95% confidence interval [CI]: 89.5, 98.8), with 73.4% (95% CI: 63.3, 82.0) achieving complete response. The median duration of response was not reached (95% CI: 18.0 months, NR) and the 1-year remission rate was 81% (95% CI: 71, 88). Serious adverse reactions occurred in 26% of patients, most often due to cytokine release syndrome (CRS), neurologic toxicity, and febrile neutropenia. CRS occurred in 59% (Grade 3: 1%) of patients and neurologic toxicities occurred in 15% (Grade 3: 2%). As a condition of accelerated approval, post marketing studies were required to verify the clinical benefit of lisocabtagene maraleucel in R/R FL. This article summarizes key aspects of the regulatory review.
- 15 July 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
FDA Approval Summary: Lisocabtagene Maraleucel for Relapsed or Refractory Follicular Lymphoma
In May 2024, the FDA granted accelerated approval to lisocabtagene maraleucel for the treatment of adults with relapsed or refractory (R/R) follicular lymphoma (FL) who have received two or more prior lines of systemic therapy. The single-arm, open-label, multicenter, phase 2 TRANSCEND-FL trial evaluating a single dose of lisocabtagene maraleucel in adults with R/R indolent non-Hodgkin lymphoma supported the FL indication. The trial enrolled 139 patients with R/R FL, including 107 with two or more prior lines of therapy. Of the 107 patients, 94 patients comprised the primary efficacy population and the independent review committee-assessed overall response rate was 95.7% (95% confidence interval [CI]: 89.5, 98.8), with 73.4% (95% CI: 63.3, 82.0) achieving complete response. The median duration of response was not reached (95% CI: 18.0 months, NR) and the 1-year remission rate was 81% (95% CI: 71, 88). Serious adverse reactions occurred in 26% of patients, most often due to cytokine release syndrome (CRS), neurologic toxicity, and febrile neutropenia. CRS occurred in 59% (Grade 3: 1%) of patients and neurologic toxicities occurred in 15% (Grade 3: 2%). As a condition of accelerated approval, post marketing studies were required to verify the clinical benefit of lisocabtagene maraleucel in R/R FL. This article summarizes key aspects of the regulatory review.
- 7 February 2024
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 30 (11) , 2309-2316
FDA Approval Summary: Lisocabtagene Maraleucel for Second-Line Treatment of Large B-Cell Lymphoma
In June 2022, the FDA extended the indication for lisocabtagene maraleucel (liso-cel) to include adults with large B-cell lymphoma (LBCL) who have refractory disease or relapse within 12 months of first-line chemoimmunotherapy (CIT), as well as transplant-ineligible adults with refractory disease or relapse after first-line CIT. Two clinical trials evaluating a single infusion of liso-cel preceded by lymphodepleting chemotherapy supported the second-line indications. TRANSFORM is a randomized, phase 3, open-label trial comparing liso-cel with standard second-line therapy, including planned autologous hematopoietic stem cell transplantation (HSCT), in 184 transplant-eligible patients. On interim analysis, event-free survival (EFS) by independent review committee (IRC) assessment was statistically significantly improved for the liso-cel arm, with a stratified hazard ratio of 0.34 [95% confidence interval (CI), 0.22–0.51; P < 0.0001]; the estimated median EFS was 10.1 months in the liso-cel arm versus 2.3 months in the control arm. PILOT is a single-arm phase 2 trial of second-line liso-cel in patients who were transplant-ineligible due to age or comorbidities but had adequate organ function for chimeric antigen receptor (CAR) T-cell therapy. Among 61 patients who received liso-cel (median age, 74 years), the IRC-assessed complete response rate was 54% (95% CI, 41–67). Among patients achieving complete response, the estimated 1-year rate of continued response was 68% (95% CI, 45–83). Of the 268 patients combined who received liso-cel as second-line therapy for LBCL, cytokine release syndrome occurred in 45% (Grade 3, 1.3%) and CAR T-cell–associated neurologic toxicities occurred in 27% (Grade 3, 7%), warranting a continued risk evaluation and mitigation strategy.
- 7 February 2024
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 30 (11) , 2309-2316
FDA Approval Summary: Lisocabtagene Maraleucel for Second-Line Treatment of Large B-Cell Lymphoma
In June 2022, the FDA extended the indication for lisocabtagene maraleucel (liso-cel) to include adults with large B-cell lymphoma (LBCL) who have refractory disease or relapse within 12 months of first-line chemoimmunotherapy (CIT), as well as transplant-ineligible adults with refractory disease or relapse after first-line CIT. Two clinical trials evaluating a single infusion of liso-cel preceded by lymphodepleting chemotherapy supported the second-line indications. TRANSFORM is a randomized, phase 3, open-label trial comparing liso-cel with standard second-line therapy, including planned autologous hematopoietic stem cell transplantation (HSCT), in 184 transplant-eligible patients. On interim analysis, event-free survival (EFS) by independent review committee (IRC) assessment was statistically significantly improved for the liso-cel arm, with a stratified hazard ratio of 0.34 [95% confidence interval (CI), 0.22–0.51; P < 0.0001]; the estimated median EFS was 10.1 months in the liso-cel arm versus 2.3 months in the control arm. PILOT is a single-arm phase 2 trial of second-line liso-cel in patients who were transplant-ineligible due to age or comorbidities but had adequate organ function for chimeric antigen receptor (CAR) T-cell therapy. Among 61 patients who received liso-cel (median age, 74 years), the IRC-assessed complete response rate was 54% (95% CI, 41–67). Among patients achieving complete response, the estimated 1-year rate of continued response was 68% (95% CI, 45–83). Of the 268 patients combined who received liso-cel as second-line therapy for LBCL, cytokine release syndrome occurred in 45% (Grade 3, 1.3%) and CAR T-cell–associated neurologic toxicities occurred in 27% (Grade 3, 7%), warranting a continued risk evaluation and mitigation strategy.
- 9 November 2023
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 63 (S2) , S110-S116
Dosing Strategy of Immunoglobulin (IgG) Replacement Therapies in Obese and Overweight Patients with Primary Immunodeficiency Diseases (PIDDs): A Meta‐Analysis of Clinical Trials
The current dosing strategy of immune globulin products for the treatment of primary immunodeficiency diseases (PIDDs) in the USA is based on total body weight (BW). The aim of our study was to assess the relationship between dose and trough level, and to determine whether an alternative dosing strategy should be considered for patients who are overweight or obese. We analyzed data in a total of 533 patients from 11 studies. We modeled the relationship between trough level and dose per week using a linear mixed model. We used an over‐dispersed Poisson model to model the relationship between infection and trough level. In these analyses, we then combined the study‐specific treatment effects using a random‐effect or fixed‐effect model. The mean administered dose per week was 9.77, 14.00, or 18.17 g in patients who were normal weight, overweight, or obese, respectively. Compared with a patient of normal weight, a 1 g increase in dose per week in a patient who was overweight was associated with a smaller increase in the trough level, 0.08 g/L less (95%CI –0.14 to –0.03 g/L), and a 1 g increase in dose per week in a patient who was obese was associated with a much smaller increase in trough level, 0.01 g/L less (95% CI –0.07 to 0.06 g/L). Last, for a 1 unit (g/L) increase in trough level, the expected number of infections remained the same, with a multiplicative factor of 1.01 (95%CI 0.98‐1.04). Overall, we found no compelling evidence to justify a reconsideration of the current dosing strategy based on total BW for patients with PIDDs who are overweight or obese.
- 9 November 2023
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 63 (S2) , S110-S116
Dosing Strategy of Immunoglobulin (IgG) Replacement Therapies in Obese and Overweight Patients with Primary Immunodeficiency Diseases (PIDDs): A Meta‐Analysis of Clinical Trials
The current dosing strategy of immune globulin products for the treatment of primary immunodeficiency diseases (PIDDs) in the USA is based on total body weight (BW). The aim of our study was to assess the relationship between dose and trough level, and to determine whether an alternative dosing strategy should be considered for patients who are overweight or obese. We analyzed data in a total of 533 patients from 11 studies. We modeled the relationship between trough level and dose per week using a linear mixed model. We used an over‐dispersed Poisson model to model the relationship between infection and trough level. In these analyses, we then combined the study‐specific treatment effects using a random‐effect or fixed‐effect model. The mean administered dose per week was 9.77, 14.00, or 18.17 g in patients who were normal weight, overweight, or obese, respectively. Compared with a patient of normal weight, a 1 g increase in dose per week in a patient who was overweight was associated with a smaller increase in the trough level, 0.08 g/L less (95%CI –0.14 to –0.03 g/L), and a 1 g increase in dose per week in a patient who was obese was associated with a much smaller increase in trough level, 0.01 g/L less (95% CI –0.07 to 0.06 g/L). Last, for a 1 unit (g/L) increase in trough level, the expected number of infections remained the same, with a multiplicative factor of 1.01 (95%CI 0.98‐1.04). Overall, we found no compelling evidence to justify a reconsideration of the current dosing strategy based on total BW for patients with PIDDs who are overweight or obese.
- 24 February 2023
- Published by Elsevier in International Immunopharmacology
- Vol. 117, 109914
Pharmacokinetics of antibodies during pregnancy: General pharmacokinetics and pregnancy related physiological changes (Part 1)
- 24 February 2023
- Published by Elsevier in International Immunopharmacology
- Vol. 117, 109914
Pharmacokinetics of antibodies during pregnancy: General pharmacokinetics and pregnancy related physiological changes (Part 1)
- 24 February 2023
- Published by Elsevier in International Immunopharmacology
- Vol. 119, 109915
Pharmacokinetics of antibodies during Pregnancy: Impact of pregnancy on the pharmacokinetics of antibodies (Part 2)
- 24 February 2023
- Published by Elsevier in International Immunopharmacology
- Vol. 119, 109915
Pharmacokinetics of antibodies during Pregnancy: Impact of pregnancy on the pharmacokinetics of antibodies (Part 2)